We invest to turn visionary ideas and science into tangible outcomes.
Our Story
Leksell Social Ventures was founded by the Leksell family, drawing on a legacy of entrepreneurship and impact. Inspired by the family’s journey of founding and building Elekta—where innovation made precision radiation therapy accessible worldwide—we know that meaningful change takes both vision and investment. At Leksell Social Ventures our mission is to combine entrepreneurial drive with strategic capital to create lasting social impact.
Investment Approach
Our investment approach is two-pronged in the sense that it aims to support both unique scientific innovations as well as the necessary implementation of novel methods and therapies. This allows us to work with the leading researchers and entrepreneurs in the life science community - as well as the policy makers and civil servants of the public sector. A way for us to make sure innovation turns into tangible outcomes.
After validating our approach over the past years through our previous investments, we are now scaling this strategy in both strands to further accelerate our impact.
Early-Stage Life Science
We are long-term partners, investing in early and science-driven companies throughout their journey—especially, but not exlusively, in the fields of diagnostics, biotech, and data-driven life sciences. Our commitment extends beyond capital, helping promising ventures evolve into transformational leaders in their field, delivering solutions that improve health and wellbeing for all.
Outcomes Models
We invest in initiatives that use rigorous, data-driven outcomes models—enabling us to validate, invest in, and scale what works across the four pillars of society: the private sector, public sector, academia, and the non-profit world. This approach ensures that our capital drives evidence-based solutions with measurable results, wherever the need is greatest.
Portfolio
Early-Stage Life Science
Swedish life science technology company pioneering innovations in epigenetic research. Founded in 2020 as a spin-off from Karolinska Institutet, Epigenica has developed the EpiFinder™ platform—a first-in-class, high-throughput, multiplexed ChIP-seq technology that enables researchers to analyze multiple epigenetic markers across many samples simultaneously, with unprecedented speed, scalability, and affordability.
More to come this autumn.
We look forward to presenting more investments later this year, all aimed at driving innovation and impact in the life science space.
PREVIOUS INVESTMENTS
Outcomes Models
The Outcomes Fund
Investment fund: Financing for a smarter welfare.
As a strategic seed and then later anchor investor in UFO, we continue to build on our previous experience with outcomes models by supporting this strategic initiative, enabling a platform for all Nordic outcomes financing. The fund has to date made the following investments in outcomes models:
￭ Härnösand Social Outcomes Contract on Elderly Care
￭ Gävle Social Outcomes Contract on Reading Ability
￭ Söderköping Social Outcomes Contract on Elderly Care
￭ Österåker Social Outcomes Contract on Primary Prevention
PREVIOUS INVESTMENTS
